We treated keratinocytes with IL-33 (100 ng/mL) and IL-17 (100 ng/mL) for 2, 6, and 24 h, respectively. The cells were detached from the cultured dishes by trypsin. The cells were fixed and holed by 1% Saponin for 30 min in room air. We stained the cells with 1:500 Rabbit (Genetex,
GTX101395, San Antonio, TX, USA) overnight at 4 °C. Then, the cells were bound by Goat anti-rabbit IgG-568 antibody (secondary antibody) for 1 h in room air. We then measured the expressions of ACE2 by flow cytometry (BD Biosciences, San Jose, CA, USA).
The following cytokines and antibodies were used: IL-33: PeproTech #200-33, 100 ng/mL; IL-17: PeproTech #200-17, 100 ng/mL; ACE2: Rabbit, Genetex,
GTX101395; Isotype: Rabbit IgG; secondary antibody: Goat anti-rabbit IgG-568.
In order to validate that IL-33 indeed enhances the expression of ACE2 in keratinocytes, we used an immunofluorescent examination to measure the expression of ACE2 in keratinocytes treated with IL-33. Furthermore, we were interested in the mechanism through which IL-33 enhances the expression of ACE2. Therefore, in order to test this hypothesis, inhibitors of ERK (PD98059) or STAT3 (STA21) were added to the keratinocytes treated with IL-33.
Lin E.C, & Hong C.H. (2022). IL-33 Enhances ACE2 Expression on Epidermal Keratinocytes in Atopic Dermatitis: A Plausible Issue for SARS-CoV-2 Transmission in Inflamed Atopic Skin. Biomedicines, 10(5), 1183.